High Bone Mass Associated With Breast Cancer Risk In Postmenopausal Women

February 27, 1997

Women with the highest bone mass are at a much greater risk of postmenopausal breast cancer than those with lower bone mass, according to the results of a long-term epidemiological study supported by the National Institutes of Health (NIH). The study's results are published in the February 27, 1997, issue of the New England Journal of Medicine.

"This report confirms a strong association between high bone mass and increased risk of breast cancer and indicates a need for further studies to examine these risks and determine intervention where appropriate," said Dr. Claude Lenfant, director of the National Heart, Lung, and Blood Institute (NHLBI) at the NIH.

Although investigators have identified a connection between estrogen and the development of breast cancer, it has been difficult to adequately measure estrogen exposure over time. "Bone mass may be a way of summarizing the body's cumulative exposure to estrogen, and therefore, might represent a potent tool for predicting who is at greatest risk of breast cancer," said Dr. Douglas Kiel, a co-author of the study and Associate Director of Medical Research at the Hebrew Rehabilitation Center for the Aged.

The study examined 1,373 women who received hand x-rays between 1967 and 1970 as part of the NHLBI's Framingham Heart Study, an ongoing epidemiological study in Framingham, Massachusetts. Using the x-rays, the researchers calculated the thickness of a bone in each woman's hand to determine its density. These women were then monitored over a 26-year period, during which time 91 women developed postmenopausal breast cancer. After adjusting for multiple breast cancer risk factors, researchers determined that women in the highest bone mass group had 3.5 times the risk of getting breast cancer compared to those in the lowest quartile of bone mass.

A variety of factors contribute to both maximizing bone mass and influencing breast development and the risk of breast cancer, according to Dr. Joan McGowan, director of the Musculoskeletal Diseases Branch of the National Institute of Arthritis and Musculoskeletal and Skin Diseases. "We need to clarify if estrogen is the link between bone mass and breast cancer, and if it is, whether it is lifetime exposure or effects that occur at a critical period, such as adolescence," said Dr. McGowan.

Although this study did not investigate the direct connection between estrogen levels or hormone replacement therapy (HRT) and breast cancer risk, it adds to the increasing evidence about the effects of estrogen, said Dr. Lenfant. However, he also cautioned that the findings should be kept in perspective since, for most women, estrogen may provide crucial benefits against heart disease and osteoporosis.

Heart disease is the leading cause of death among American women. While about 44,000 women died of breast cancer in 1994, approximately 370,000 died of heart disease.

The Postmenopausal Estrogen/Progestin Interventions Trial (PEPI), an NHLBI-administered study, found that HRT helps improve some heart disease risk factors. For instance, it causes significant increases in HDL or "good" cholesterol and decreases in LDL or "bad" cholesterol.

The PEPI study also found that HRT increases bone density, helping to reduce the risk of osteoporosis, a severe thinning of the bones that can lead to an increased risk of bone fractures and serious complications including pain, loss of mobility, and death. About 25 million people in the U.S. have or are at risk of developing osteoporosis.

"Additional research is needed to pinpoint the modifiable risks associated with cancer, heart disease, and osteoporosis, and how they interrelate. For example, the NIH Women's Health Initiative is currently conducting a large, randomized clinical trial to determine the direct benefits and risks of HRT on postmenopausal women," said Dr. Lenfant.

For postmenopausal women who need to make treatment decisions now, before ongoing study results are available, Dr. Lenfant advised women to consult their physicians and weigh their individual health risks before deciding on the best course of action.

The study was conducted by lead author Dr. Yuqing Zhang and other researchers and supported by the National Heart, Lung, and Blood Institute, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Cancer Institute, components of the NIH.

Dr. Douglas Kiel is available for comment at (617) 325-8000 x384. Dr. Joan McGowan is also available for comment and can be reached through the NIAMS Communications Office at (301) 496-8190. In addition, Dr. David Felson, co-author of the study, may be reached through the Boston University School of Medicine Communications Office at (617) 638-8491. For background information on the Framingham Heart Study and to interview Dr. Daniel Levy, director of Framingham, contact the NHLBI Communications Office at (301) 496-4236.

NHLBI press releases, fact sheets, and other materials are available online at the following website: http://www.nhlbi.nih.gov/nhlbi/nhlbi.htm.

NIH/National Heart, Lung and Blood Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.